Sodium-glucose co-transporter-2 (SGLT2) inhibitors have demonstrated benefits in promoting renal sodium excretion and improving glycemic control, thereby mitigating hypertension and extracellular fluid overload [118]. This evidence concerns the gene SLC5A2 and Hypertension.